How Biotech Startups Are Using AI to Find New Antibiotics

Antibiotic resistance is a growing global crisis, but a new wave of biotech startups is using artificial intelligence to discover novel antibiotics faster and cheaper than traditional methods. In this episode, Lucas and Luna examine how AI-powered platforms are sifting through millions of molecular combinations to identify promising drug candidates. They focus on the case of Phare Bio, a startup spun out of the MIT Antibiotics Project, which recently secured $45 million in Series A funding to advance its AI-driven discovery engine. Lucas explains why the antibiotic pipeline has been dry for decades—low profitability drives big pharma away—and how AI changes the economic calculus. Luna challenges whether AI can overcome the biological hurdles that have stymied traditional screening. The hosts also discuss the role of public-private partnerships like the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, in funding early-stage research. Along the way, they touch on the unique challenge of avoiding AI hallucination in molecule generation and why startups are focusing on Gram-negative bacteria as a priority. This episode offers a grounded look at how machine learning is being applied to one of medicine's hardest problems, without hype. #AI #Antibiotics #Biotech #DrugDiscovery #PhareBio #MachineLearning #AntimicrobialResistance #GramNegativeBacteria #Startups #Pharmaceuticals #Business #Technology #FexingoBusiness #BusinessPodcast #BiotechStartup #CARBX #MIT #SeriesA Keep every episode free: buymeacoffee.com/fexingo